Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Intranasal micro-optical coherence tomography imaging for cystic fibrosis studies.

Leung HM, Birket SE, Hyun C, Ford TN, Cui D, Solomon GM, Shei RJ, Adewale AT, Lenzie AR, Fernandez-Petty CM, Zheng H, Palermo JH, Cho DY, Woodworth BA, Yonker LM, Hurley BP, Rowe SM, Tearney GJ.

Sci Transl Med. 2019 Aug 7;11(504). pii: eaav3505. doi: 10.1126/scitranslmed.aav3505.

PMID:
31391319
2.

Taskforce recommends coordinated effort to improve clinical research conduct and find highly effective CFTR-directed treatment for rare mutations.

Solomon GM, Nichols DP.

J Cyst Fibros. 2019 Jul 4. pii: S1569-1993(19)30818-5. doi: 10.1016/j.jcf.2019.06.014. [Epub ahead of print] No abstract available.

PMID:
31279576
3.

The California Safer Consumer Products Program: Evaluating a Novel Chemical Policy Strategy.

Solomon GM, Hoang A, Reynolds P.

New Solut. 2019 Aug;29(2):224-241. doi: 10.1177/1048291119850105. Epub 2019 May 27. No abstract available.

PMID:
31132920
4.

Employment of an algorithm of care including chest physiotherapy results in reduced hospitalizations and stability of lung function in bronchiectasis.

Powner J, Nesmith A, Kirkpatrick DP, Nichols JK, Bermingham B, Solomon GM.

BMC Pulm Med. 2019 Apr 25;19(1):82. doi: 10.1186/s12890-019-0844-4.

5.

Proline-Glycine-Proline Peptides Are Critical in the Development of Smoke-Induced Emphysema.

Abdul Roda M, Xu X, Abdalla TH, Sadik M, Szul T, Bratcher PE, Viera L, Solomon GM, Wells JM, McNicholas CM, Redegeld FA, Folkerts G, Blalock JE, Gaggar A.

Am J Respir Cell Mol Biol. 2019 Apr 8. doi: 10.1165/rcmb.2018-0216OC. [Epub ahead of print]

PMID:
30958968
6.

The economic burden of bronchiectasis - known and unknown: a systematic review.

Goeminne PC, Hernandez F, Diel R, Filonenko A, Hughes R, Juelich F, Solomon GM, Upton A, Wichmann K, Xu W, Chalmers JD.

BMC Pulm Med. 2019 Feb 28;19(1):54. doi: 10.1186/s12890-019-0818-6.

7.

Muc5b overexpression causes mucociliary dysfunction and enhances lung fibrosis in mice.

Hancock LA, Hennessy CE, Solomon GM, Dobrinskikh E, Estrella A, Hara N, Hill DB, Kissner WJ, Markovetz MR, Grove Villalon DE, Voss ME, Tearney GJ, Carroll KS, Shi Y, Schwarz MI, Thelin WR, Rowe SM, Yang IV, Evans CM, Schwartz DA.

Nat Commun. 2018 Dec 18;9(1):5363. doi: 10.1038/s41467-018-07768-9.

8.

Colocolonic intussusception in an adult cystic fibrosis patient.

Timothy Adewale A, Rowe SM, Solomon GM.

J Cyst Fibros. 2019 Mar;18(2):e11-e13. doi: 10.1016/j.jcf.2018.11.013. Epub 2018 Nov 29.

PMID:
30503033
9.

Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis.

Sermet-Gaudelus I, Clancy JP, Nichols DP, Nick JA, De Boeck K, Solomon GM, Mall MA, Bolognese J, Bouisset F, den Hollander W, Paquette-Lamontagne N, Tomkinson N, Henig N, Elborn JS, Rowe SM.

J Cyst Fibros. 2019 Jul;18(4):536-542. doi: 10.1016/j.jcf.2018.10.015. Epub 2018 Nov 19.

10.

Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD).

Solomon GM, Bronsveld I, Hayes K, Wilschanski M, Melotti P, Rowe SM, Sermet-Gaudelus I.

J Vis Exp. 2018 Sep 13;(139). doi: 10.3791/57006.

PMID:
30272672
11.

Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction and Radiographic Bronchiectasis in Current and Former Smokers: A Cross-Sectional Study.

Teerapuncharoen K, Wells JM, Raju SV, Raraigh KS, Atalar Aksit M, Cutting GR, Rasmussen L, Nath PH, Bhatt SP, Solomon GM, Dransfield MT, Rowe SM.

Ann Am Thorac Soc. 2019 Jan;16(1):150-153. doi: 10.1513/AnnalsATS.201805-325RL. No abstract available.

PMID:
30230364
12.

CFTR modulator theratyping: Current status, gaps and future directions.

Clancy JP, Cotton CU, Donaldson SH, Solomon GM, VanDevanter DR, Boyle MP, Gentzsch M, Nick JA, Illek B, Wallenburg JC, Sorscher EJ, Amaral MD, Beekman JM, Naren AP, Bridges RJ, Thomas PJ, Cutting G, Rowe S, Durmowicz AG, Mense M, Boeck KD, Skach W, Penland C, Joseloff E, Bihler H, Mahoney J, Borowitz D, Tuggle KL.

J Cyst Fibros. 2019 Jan;18(1):22-34. doi: 10.1016/j.jcf.2018.05.004. Epub 2018 Jun 20. Review.

13.

Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations.

Guimbellot J, Solomon GM, Baines A, Heltshe SL, VanDalfsen J, Joseloff E, Sagel SD, Rowe SM; GOALe(2) Investigators.

J Cyst Fibros. 2019 Jan;18(1):102-109. doi: 10.1016/j.jcf.2018.04.004. Epub 2018 Apr 21.

PMID:
29685811
14.

Seeing cilia: imaging modalities for ciliary motion and clinical connections.

Peabody JE, Shei RJ, Bermingham BM, Phillips SE, Turner B, Rowe SM, Solomon GM.

Am J Physiol Lung Cell Mol Physiol. 2018 Jun 1;314(6):L909-L921. doi: 10.1152/ajplung.00556.2017. Epub 2018 Mar 1. Review.

15.

Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients.

Garcia BA, Carden JL, Goodwin DL, Smith TA, Gaggar A, Leon K, Antony VB, Rowe SM, Solomon GM.

BMC Pulm Med. 2018 Feb 14;18(1):35. doi: 10.1186/s12890-018-0594-8.

16.

MicroRNA-145 Antagonism Reverses TGF-β Inhibition of F508del CFTR Correction in Airway Epithelia.

Lutful Kabir F, Ambalavanan N, Liu G, Li P, Solomon GM, Lal CV, Mazur M, Halloran B, Szul T, Gerthoffer WT, Rowe SM, Harris WT.

Am J Respir Crit Care Med. 2018 Mar 1;197(5):632-643. doi: 10.1164/rccm.201704-0732OC.

17.

The therapeutic potential of CFTR modulators for COPD and other airway diseases.

Solomon GM, Fu L, Rowe SM, Collawn JF.

Curr Opin Pharmacol. 2017 Jun;34:132-139. doi: 10.1016/j.coph.2017.09.013. Epub 2017 Nov 10. Review.

18.

Systematic Computational Identification of Variants That Activate Exonic and Intronic Cryptic Splice Sites.

Lee M, Roos P, Sharma N, Atalar M, Evans TA, Pellicore MJ, Davis E, Lam AN, Stanley SE, Khalil SE, Solomon GM, Walker D, Raraigh KS, Vecchio-Pagan B, Armanios M, Cutting GR.

Am J Hum Genet. 2017 May 4;100(5):751-765. doi: 10.1016/j.ajhg.2017.04.001.

19.

A multiple reader scoring system for Nasal Potential Difference parameters.

Solomon GM, Liu B, Sermet-Gaudelus I, Fajac I, Wilschanski M, Vermeulen F, Rowe SM.

J Cyst Fibros. 2017 Sep;16(5):573-578. doi: 10.1016/j.jcf.2017.04.011. Epub 2017 Apr 29.

20.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.

Sanders DB, Solomon GM, Beckett VV, West NE, Daines CL, Heltshe SL, VanDevanter DR, Spahr JE, Gibson RL, Nick JA, Marshall BC, Flume PA, Goss CH; STOP Study Group.

J Cyst Fibros. 2017 Sep;16(5):592-599. doi: 10.1016/j.jcf.2017.04.005. Epub 2017 Apr 29.

21.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.

West NE, Beckett VV, Jain R, Sanders DB, Nick JA, Heltshe SL, Dasenbrook EC, VanDevanter DR, Solomon GM, Goss CH, Flume PA; STOP investigators.

J Cyst Fibros. 2017 Sep;16(5):600-606. doi: 10.1016/j.jcf.2017.04.003. Epub 2017 Apr 29.

22.

Assessment of ciliary phenotype in primary ciliary dyskinesia by micro-optical coherence tomography.

Solomon GM, Francis R, Chu KK, Birket SE, Gabriel G, Trombley JE, Lemke KL, Klena N, Turner B, Tearney GJ, Lo CW, Rowe SM.

JCI Insight. 2017 Mar 9;2(5):e91702. doi: 10.1172/jci.insight.91702.

23.

Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR.

Donaldson SH, Solomon GM, Zeitlin PL, Flume PA, Casey A, McCoy K, Zemanick ET, Mandagere A, Troha JM, Shoemaker SA, Chmiel JF, Taylor-Cousar JL.

J Cyst Fibros. 2017 May;16(3):371-379. doi: 10.1016/j.jcf.2017.01.009. Epub 2017 Feb 13.

24.

Flexible, high-resolution micro-optical coherence tomography endobronchial probe toward in vivo imaging of cilia.

Cui D, Chu KK, Yin B, Ford TN, Hyun C, Leung HM, Gardecki JA, Solomon GM, Birket SE, Liu L, Rowe SM, Tearney GJ.

Opt Lett. 2017 Feb 15;42(4):867-870. doi: 10.1364/OL.42.000867.

25.

Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation.

Mutyam V, Libby EF, Peng N, Hadjiliadis D, Bonk M, Solomon GM, Rowe SM.

J Cyst Fibros. 2017 Jan;16(1):24-29. doi: 10.1016/j.jcf.2016.09.005. Epub 2016 Oct 1.

26.

In vivo imaging of airway cilia and mucus clearance with micro-optical coherence tomography.

Chu KK, Unglert C, Ford TN, Cui D, Carruth RW, Singh K, Liu L, Birket SE, Solomon GM, Rowe SM, Tearney GJ.

Biomed Opt Express. 2016 Jun 2;7(7):2494-505. doi: 10.1364/BOE.7.002494. eCollection 2016 Jul 1.

27.

Dual SMAD Signaling Inhibition Enables Long-Term Expansion of Diverse Epithelial Basal Cells.

Mou H, Vinarsky V, Tata PR, Brazauskas K, Choi SH, Crooke AK, Zhang B, Solomon GM, Turner B, Bihler H, Harrington J, Lapey A, Channick C, Keyes C, Freund A, Artandi S, Mense M, Rowe S, Engelhardt JF, Hsu YC, Rajagopal J.

Cell Stem Cell. 2016 Aug 4;19(2):217-231. doi: 10.1016/j.stem.2016.05.012. Epub 2016 Jun 16.

28.

Pilot evaluation of ivacaftor for chronic bronchitis.

Solomon GM, Hathorne H, Liu B, Raju SV, Reeves G, Acosta EP, Dransfield MT, Rowe SM.

Lancet Respir Med. 2016 Jun;4(6):e32-3. doi: 10.1016/S2213-2600(16)30047-9. Epub 2016 May 16. No abstract available.

29.

Airway Progenitor Clone Formation Is Enhanced by Y-27632-Dependent Changes in the Transcriptome.

Reynolds SD, Rios C, Wesolowska-Andersen A, Zhuang Y, Pinter M, Happoldt C, Hill CL, Lallier SW, Cosgrove GP, Solomon GM, Nichols DP, Seibold MA.

Am J Respir Cell Mol Biol. 2016 Sep;55(3):323-36. doi: 10.1165/rcmb.2015-0274MA.

30.

Therapeutic Approaches to Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis.

Solomon GM, Raju SV, Dransfield MT, Rowe SM.

Ann Am Thorac Soc. 2016 Apr;13 Suppl 2:S169-76. doi: 10.1513/AnnalsATS.201509-601KV. Review.

31.

Neutrophil Fates in Bronchiectasis and Alpha-1 Antitrypsin Deficiency.

Russell DW, Gaggar A, Solomon GM.

Ann Am Thorac Soc. 2016 Apr;13 Suppl 2:S123-9. doi: 10.1513/AnnalsATS.201512-805KV.

32.

Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomy.

Birket SE, Chu KK, Houser GH, Liu L, Fernandez CM, Solomon GM, Lin V, Shastry S, Mazur M, Sloane PA, Hanes J, Grizzle WE, Sorscher EJ, Tearney GJ, Rowe SM.

Am J Physiol Lung Cell Mol Physiol. 2016 May 15;310(10):L928-39. doi: 10.1152/ajplung.00395.2015. Epub 2016 Mar 11.

33.

Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis and Other Diseases of Mucus Clearance.

Raju SV, Solomon GM, Dransfield MT, Rowe SM.

Clin Chest Med. 2016 Mar;37(1):147-58. doi: 10.1016/j.ccm.2015.11.003. Epub 2015 Dec 24. Review.

34.

Cumulative Environmental Impacts: Science and Policy to Protect Communities.

Solomon GM, Morello-Frosch R, Zeise L, Faust JB.

Annu Rev Public Health. 2016;37:83-96. doi: 10.1146/annurev-publhealth-032315-021807. Epub 2016 Jan 6. Review.

PMID:
26735429
35.

Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.

Solomon GM, Marshall SG, Ramsey BW, Rowe SM.

Pediatr Pulmonol. 2015 Oct;50 Suppl 40:S3-S13. doi: 10.1002/ppul.23240. Epub 2015 Jun 19. Review.

36.

Screening for Chemical Contributions to Breast Cancer Risk: A Case Study for Chemical Safety Evaluation.

Schwarzman MR, Ackerman JM, Dairkee SH, Fenton SE, Johnson D, Navarro KM, Osborne G, Rudel RA, Solomon GM, Zeise L, Janssen S.

Environ Health Perspect. 2015 Dec;123(12):1255-64. doi: 10.1289/ehp.1408337. Epub 2015 Jun 2. Review.

37.

Improved clinical and radiographic outcomes after treatment with ivacaftor in a young adult with cystic fibrosis with the P67L CFTR mutation.

Yousef S, Solomon GM, Brody A, Rowe SM, Colin AA.

Chest. 2015 Mar;147(3):e79-e82. doi: 10.1378/chest.14-1198.

PMID:
25732475
38.

Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease.

Taylor-Cousar JL, Wiley C, Felton LA, St Clair C, Jones M, Curran-Everett D, Poch K, Nichols DP, Solomon GM, Saavedra MT, Accurso FJ, Nick JA.

J Cyst Fibros. 2015 Mar;14(2):228-36. doi: 10.1016/j.jcf.2014.10.006. Epub 2014 Nov 13.

39.

IP-10 is a potential biomarker of cystic fibrosis acute pulmonary exacerbations.

Solomon GM, Frederick C, Zhang S, Gaggar A, Harris T, Woodworth BA, Steele C, Rowe SM.

PLoS One. 2013 Aug 16;8(8):e72398. doi: 10.1371/journal.pone.0072398. eCollection 2013.

40.

Mycobacterium abscessus induces a limited pattern of neutrophil activation that promotes pathogen survival.

Malcolm KC, Nichols EM, Caceres SM, Kret JE, Martiniano SL, Sagel SD, Chan ED, Caverly L, Solomon GM, Reynolds P, Bratton DL, Taylor-Cousar JL, Nichols DP, Saavedra MT, Nick JA.

PLoS One. 2013;8(2):e57402. doi: 10.1371/journal.pone.0057402. Epub 2013 Feb 25.

41.

Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.

Rowe SM, Reeves G, Hathorne H, Solomon GM, Abbi S, Renard D, Lock R, Zhou P, Danahay H, Clancy JP, Waltz DA.

Chest. 2013 Jul;144(1):200-207. doi: 10.1378/chest.12-2431.

42.

Ethical challenges of caring for VIPs in the rehabilitation setting.

Kirshblum S, Solomon GM, Brashler R, Kirschner KL.

PM R. 2012 Jul;4(7):517-20. doi: 10.1016/j.pmrj.2012.05.006. No abstract available.

PMID:
22814729
43.

Six climate change-related events in the United States accounted for about $14 billion in lost lives and health costs.

Knowlton K, Rotkin-Ellman M, Geballe L, Max W, Solomon GM.

Health Aff (Millwood). 2011 Nov;30(11):2167-76. doi: 10.1377/hlthaff.2011.0229.

PMID:
22068410
44.

Seafood contamination after the BP Gulf oil spill and risks to vulnerable populations: a critique of the FDA risk assessment.

Rotkin-Ellman M, Wong KK, Solomon GM.

Environ Health Perspect. 2012 Feb;120(2):157-61. doi: 10.1289/ehp.1103695. Epub 2011 Oct 12.

45.

Gulf oil spill air quality monitoring: lessons learned to improve emergency response.

Rotkin-Ellman M, Navarro KM, Solomon GM.

Environ Sci Technol. 2010 Nov 15;44(22):8365-6. doi: 10.1021/es103323v. Epub 2010 Oct 21. No abstract available.

PMID:
20964292
46.

Health effects of the Gulf oil spill.

Solomon GM, Janssen S.

JAMA. 2010 Sep 8;304(10):1118-9. doi: 10.1001/jama.2010.1254. Epub 2010 Aug 16. No abstract available.

PMID:
20713544
47.

Toxicity testing in the 21st century: a vision and a strategy.

Krewski D, Acosta D Jr, Andersen M, Anderson H, Bailar JC 3rd, Boekelheide K, Brent R, Charnley G, Cheung VG, Green S Jr, Kelsey KT, Kerkvliet NI, Li AA, McCray L, Meyer O, Patterson RD, Pennie W, Scala RA, Solomon GM, Stephens M, Yager J, Zeise L.

J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):51-138. doi: 10.1080/10937404.2010.483176.

48.

An international randomized multicenter comparison of nasal potential difference techniques.

Solomon GM, Konstan MW, Wilschanski M, Billings J, Sermet-Gaudelus I, Accurso F, Vermeulen F, Levin E, Hathorne H, Reeves G, Sabbatini G, Hill A, Mayer-Hamblett N, Ashlock M, Clancy JP, Rowe SM.

Chest. 2010 Oct;138(4):919-28. doi: 10.1378/chest.10-0179. Epub 2010 May 14.

49.

Physicians' duty to be aware of and report environmental toxins.

Solomon GM, Kirkhorn SR.

Virtual Mentor. 2009 Jun 1;11(6):434-42. doi: 10.1001/virtualmentor.2009.11.6.ccas2-0906. No abstract available.

50.

Potential role of high-mobility group box 1 in cystic fibrosis airway disease.

Rowe SM, Jackson PL, Liu G, Hardison M, Livraghi A, Solomon GM, McQuaid DB, Noerager BD, Gaggar A, Clancy JP, O'Neal W, Sorscher EJ, Abraham E, Blalock JE.

Am J Respir Crit Care Med. 2008 Oct 15;178(8):822-31. doi: 10.1164/rccm.200712-1894OC. Epub 2008 Jul 24.

Supplemental Content

Loading ...
Support Center